Phosplatin Therapeutics

Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company. Its lead candidate, PT-112, is a novel chemical entity that exhibits a unique combination of properties, including best-in-class immunogenic cell death and osteotropism. Clinical data generated to date across three Phase 1 studies have demonstrated single agent anti-cancer activity and an attractive tolerability profile. The company's R&D work to date has spanned fifteen countries and been funded by private investors and family investment offices in the US, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company also sponsors an ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA (EMD Serono in the US and Canada). Results of this study have been selected for Mini Oral presentation at the upcoming ESMO 2020 Virtual Congress.